Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis
Sionna Therapeutics Inc SION.O:
SIONNA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA FOR NBD1 STABILIZERS SION-719 AND SION-451 AND ADVANCES BOTH PROGRAMS IN CLINICAL DEVELOPMENT FOR CYSTIC FIBROSIS
SIONNA THERAPEUTICS INC -NEXT TRIALS TO INITIATE IN SECOND HALF OF 2025 WITH TOPLINE DATA EXPECTED IN MID-2026
SIONNA THERAPEUTICS- SION-719 AND SION-451 WERE GENERALLY WELL TOLERATED AND ACHIEVED DESIRED PHARMACOKINETIC TARGETS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Netflix Q1 2026 Earnings Preview: After Acquisition Turmoil, Where Is This Streaming Giant’s Growth Confidence?

Why AMD Stock Popped: 12-Day Winning Rally Signals CPU Renaissance in Agentic AI Push

Why Is Ethereum Stalling While Bitcoin Surges? Will It Ever Reach $10,000?

APLD Stock Surge: How CoreWeave Lease Amendments and Delta Forge 1 Milestones De-risk the Bull Case

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Tradingkey








